Polartechnics Limited Company Summary |
|
Polartechnics Ltd (ASX: PLT) is a biomedical company specialising in screening for cervical and skin cancers. Together with CerviScreen(tm), Polartechnics has developed and manufactures TruScreen(tm), a real-time point of care cervical cancer screening device with superior performance sensitivity than Pap and related cytology methodologies. TruScreen is CE accredited and is used commercially in Asia, Middle East and Eastern Europe. Polartechnics also markets MediScan(tm), a real-time medical record system, for merging visual and text data and SolarScan(tm), a cancer-screening device for melanoma detection.
|
|
COMPANY DATA |
 |
Telephone |
+61-2-8568-5333 |
 |
|
Fax |
+61-2-8568-5399 |
|
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Healthcare |
|
|
Listed |
1987/05/08 |
|
|
Homepage |
www.polartechnics.com.au |
|
| |
Key Developments: Polartechnics Limited
 |
Australian Market Report of April 20: Market Sentiment Pushed Up
APR 20, 2009 13:00 - Article Views: 8,259
The Australian shares ended with little changes on Friday. The S&P/ASX200 index just added 1 point to 3776.7 points, while the broader All Ordinaries gained 2.5 points to 3728.1. The local market is likely to be lifted on the back of the stronger metals prices. Today Rio Tinto's Australian annual meeting will also be the market focus. |
|
 |
Polartechnics Limited (ASX:PLT) Enters Global Sexually Transmitted Infection (STI) Market With A DNA Self-Sampling Device
FEB 18, 2009 11:52 - Article Views: 2,591
Polartechnics (ASX:PLT)(PINK:PLTFF) proprietary self-sampling device, CerviScreen, has now been adapted to test for STI's including Chlamydia, Gonorrhoea and Trichomoniasis for both men and women. The new self-sampling target market for the STI device is sexually active men and women aged 15 to 50. |
|
|
Polartechnics Limited (ASX:PLT) To Launch CerviScreen(tm) With Genera Biosystems Limited and Healthscope
SEP 5, 2008 11:20 - Article Views: 4,737
Polartechnics Limited (ASX:PLT)(PINK:PLTFF) today announced it had reached a strategic agreement with its preferred business partners, Genera Biosystems and Healthscope, for the commercialisation of CerviScreen, which is a new device to identify sexually transmitted Human Papillomavirus (HPV) using self-sampled specimens. |
|
9,523 COMPANY PROFILE VIEWS |
|
This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 60) (Since Published: 1959)
|
|
|
|
ASX S&P200
ASX:PLT
